ライフサイエンスコーパス: estrogen receptor

1 r overexpression (androgen, progesterone, or estrogen receptor).

2 ed variant in WNT4 alters the binding of the estrogen receptor.

3 ly correlated with progesterone receptor and estrogen receptor.

4 nt gene fusions including a subset involving estrogen receptor.

5 suggesting nongenomic E2 effects at membrane estrogen receptors.

6 enous estrogens by binding to and activating estrogen receptors.

7 st/antagonist activity acting via endogenous estrogen receptors.

8 brane permeability, and no interference with estrogen receptors.

9 its relatively lower affinity for vertebrate estrogen receptors.

10 we showed that, in 3T3-L1 cells, E2 and the estrogen receptor 1 (ESR1) agonist PPT induced VEGFA exp

11 we demonstrate that MSI2 directly regulates estrogen receptor 1 (ESR1), which is a well-known therap

12 studies indicated that the G protein-coupled estrogen receptor 1 (GPER/GPR30) mediates these effects

13 or 30 (GPR30), also called G protein-coupled estrogen receptor 1 (GPER1), is thought to play importan

14 pression of PGC1A in H2.35 cells coactivated estrogen receptor 1 and was required for estrogen-depend

15 pressing an estrogen receptor reporter gene, estrogen receptor 1, and/or PGC1A/B.

16 ption factor (SOX11), calmodulin (CALM), and estrogen receptor 2 (ESR2A), all with a significant role

17 totoxic natural product Dragmacidin B and an estrogen receptor (2l).

18 ranscriptional activity was dependent on the estrogen receptor activated.

19 Collaborative Estrogen Receptor Activity Prediction Project.

20 Bioavailable isoflavones with selective estrogen receptor affinity show potential to prevent and

21 Finally, we find that estrogen receptor agonists elicit a behavioral fingerpri

22 The majority of human breast cancer is estrogen receptor alpha (ER) positive.

23 ox protein A1 (FOXA1) is a pioneer factor of estrogen receptor alpha (ER)-chromatin binding and funct

24 Estrogen receptor alpha (ER-alpha) is a nuclear hormone

25 demonstrate that Icaritin co-localizes with estrogen receptor alpha (ERalpha) and activates its nucl

26 Approximately 75% of breast cancers express estrogen receptor alpha (ERalpha) and depend on estrogen

27 pid metabolism and body weight by repressing estrogen receptor alpha (ERalpha) expression.

28 Somatic mutations in the estrogen receptor alpha (ERalpha) gene (ESR1), especiall

29 ctions of glucocorticoid receptors (GRs) and estrogen receptor alpha (ERalpha) in breast cancer devel

30 and mobilization, processes that depend upon estrogen receptor alpha (ERalpha) in HSCs.

31 Estrogen receptor alpha (ERalpha) is a critical prognost

32 Estrogen receptor alpha (ERalpha) is a key regulator of

33 Estrogen receptor alpha (ERalpha) is a major regulator o

34 Estrogen receptor alpha (ERalpha) is a master driver of

35 Estrogen receptor alpha (ERalpha) is an important target

36 Estrogen receptor alpha (ERalpha) is highly expressed in

37 All compounds were high affinity estrogen receptor alpha (ERalpha) ligands but displayed

38 D538G is common after endocrine therapy for estrogen receptor alpha (ERalpha) positive breast cancer

39 Almost 70% of breast cancers are estrogen receptor alpha (ERalpha) positive.

40 Estrogen receptor alpha (ERalpha) regulates gene transcr

41 The DNA-binding sites of estrogen receptor alpha (ERalpha) show great plasticity

42 cell line MCF7, which expresses a functional estrogen receptor alpha (ERalpha) signaling pathway.

43 lective loss- or gain-of-function mutants of estrogen receptor alpha (ERalpha) to define two distinct

44 ecule antagonist of the transcription factor estrogen receptor alpha (ERalpha) used to treat breast c

45 strogens drive breast carcinogenesis via the estrogen receptor alpha (ERalpha), androgens play a crit

46 Estrogen, via estrogen receptor alpha (ERalpha), exerts several benefi

47 ntermembrane space (IMS) and mediated by the estrogen receptor alpha (ERalpha), was found to upregula

48 Estradiol acts via estrogen receptor alpha (ERalpha)-expressing afferents o

49 Many estrogen receptor alpha (ERalpha)-positive breast cancer

50 hway in 20% to 40% of cases, particularly in estrogen receptor alpha (ERalpha)-positive breast cancer

51 Many estrogen receptor alpha (ERalpha)-positive breast cancer

52 which can be eliminated by an antagonist of estrogen receptor alpha (ERalpha).

53 fully applied for detection of the biomarker estrogen receptor alpha (ERalpha).

54 this effect was absent in mice lacking liver estrogen receptor alpha (Esr1) (LERKO mice).

55 uctal epithelial cells are regulated through estrogen receptor alpha (ESR1) but not estrogen receptor

56 -induced uterine cell growth, we removed the estrogen receptor alpha (Esr1) from mouse uterine stroma

57 ear receptors (NRs) [androgen receptor (Ar), estrogen receptor alpha (Esr1), estrogen receptor beta (

58 5 orders of magnitude more sensitive, by an estrogen receptor alpha (EsRalpha)-dependent mechanism.

59 uR1, depending on its activation by membrane estrogen receptor alpha (mERalpha; during diestrus) vers

60 s the estrogen receptor needed for feedback (estrogen receptor alpha [ERalpha]); kisspeptin neurons i

61 E2 substantially increases CaM binding to estrogen receptor alpha and GPER/GPR30.

62 hat promotes BC progression independently of estrogen receptor alpha expression.

63 e, in the induction of priming, regulated by estrogen receptor alpha in the nociceptor of female rats

64 Moreover, high levels of estrogen receptor alpha in these tumors enhanced the gro

65 Estrogen receptor alpha is required for oviductal transp

66 rine ILC2s was observed in mice deficient in estrogen receptor alpha or estrogen receptor beta.

67 On the other hand, SORBS3 coactivated estrogen receptor alpha signaling, leading indirectly to

68 tic variants across the ESR1 locus (encoding estrogen receptor alpha) in 118,816 subjects from three

69 Furthermore, uterine ILC2s highly expressed estrogen receptor alpha, and in vitro culture of isolate

70 hormone receptor family (androgen receptor, estrogen receptor alpha, glucocorticoid receptor, minera

71 get network, including GPER/GPR30 itself and estrogen receptor alpha, the plasma membrane Ca(2+)-ATPa

72 Moreover, estrogen receptor alpha-ir colocalized with ERbeta-EGFP

73 receptor coactivator 2, which interacts with estrogen receptor alpha.

74 CD133(hi) CSCs that expressed low levels of estrogen receptor alpha.

75 Drugs that inhibit estrogen receptor-alpha (ER) activity have been highly s

76 p) on neutralizing epigenetic aberrations in estrogen receptor-alpha (ERalpha) leading to enhanced an

77 1 (GCM1), frizzled 5 (FZD5), WNT2, Sp1, and estrogen receptor-alpha (ERalpha) mRNA, were markedly up

78 models that allow for selective deletion of estrogen receptor-alpha (ERalpha) or selective inhibitio

79 Approximately 75% of breast cancers are estrogen receptor-alpha (ERalpha) positive, underscoring

80 red methylation that preferentially affected estrogen receptor-alpha (ERalpha)-binding genes.

81 herapy resistance remains a major problem in estrogen receptor-alpha (ERalpha)-positive breast cancer

82 ntromedial hypothalamus (VMHvl) that express estrogen receptor-alpha (Esr1) and progesterone receptor

83 Sustained expression of the estrogen receptor-alpha (ESR1) drives two-thirds of brea

84 etic studies highlight the potential role of estrogen receptor-alpha (ESR1) mutations, which show inc

85 egree show a greater effect on the levels of estrogen receptor-alpha activity and nuclear factor eryt

86 terically regulated Cas9 by insertion of the estrogen receptor-alpha ligand-binding domain.

87 TNBC does not express estrogen receptor-alpha, progesterone receptor, or the H

88 athways, and with other receptors, including estrogen receptor and human epidermal growth factor rece

89 different chemotherapeutic regimens based on estrogen receptor and human epidermal growth factor rece

90 ) is a subtype of breast cancer in which the estrogen receptor and progesterone receptor are not expr

91 Women with estrogen receptor- and progesterone receptor-negative (<

92 ar-old women with left-sided, T2N1, grade 3, estrogen receptor- and progesterone receptor-negative, h

93 Estrogen receptor antagonism might be of value in reduci

94 ovariectomy or treating female mice with an estrogen receptor antagonist increased mortality, indica

95 enol red-free media or in the presence of an estrogen receptor antagonist.

96 Estrogen receptor antagonists blocked the synergistic in

97 and in vitro models to determine the role of estrogen receptor beta (ER-beta) and its ligands on adip

98 Estrogen receptor beta (ER-beta) and its selective ligan

99 Estrogen receptor beta (ERbeta) is essential for migrati

100 Moreover, siRNA-mediated knockdown of estrogen receptor beta (ERbeta), but not ERalpha, abolis

101 Estrogen effects are mediated by estrogen receptor beta (ERbeta), which reduces chromatin

102 Activation of estrogen receptor beta (ERbeta)-expressing neurons regul

103 ceptor (Ar), estrogen receptor alpha (Esr1), estrogen receptor beta (Esr2), glucocorticoid receptor (

104 rough estrogen receptor alpha (ESR1) but not estrogen receptor beta (ESR2).

105 Pharmacologic activation of estrogen receptor beta increases mitochondrial function,

106 ith sulforaphane and diarylpropionitrile, an estrogen receptor beta selective agonist, results in NRF

107 mice deficient in estrogen receptor alpha or estrogen receptor beta.

108 over, pharmacologic inhibition of microglial estrogen receptor-beta (ERbeta) function corrects the re

109 get.Significance: These findings identify an estrogen receptor-binding protein as a critical mediator

110 In contrast, estrogen receptor blocker did not affect BMP2 action.

111 e disruption of the binding affinity for the estrogen receptor, but oxidative stress and inflammation

112 CLM may attenuate signaling through the estrogen receptor by reducing levels of the estrogenic c

113 e transcription factors NFIB and YBX1 to the estrogen receptor can promote an estrogen-independent ph

114 gen-induced gene transcription by preventing Estrogen Receptor chromatin binding and by hindering the

115 as a potent ERalpha antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral

116 coexposure with ICI 182780, demonstrating an estrogen receptor dependent mechanism.

117 ted with different phenotype sets, including estrogen receptor (ER(+) or ER(-)) and human ERBB2 (HER2

118 The majority of breast cancers expresses the estrogen receptor (ER(+)) and is treated with anti-estro

119 e pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer t

120 ed gene-expression profiles in patients with estrogen receptor (ER) -positive, early-stage breast can

121 ry effects of 17beta-estradiol (non-specific estrogen receptor (ER) agonist), PPT (ERalpha-specific a

122 ted greater expression of the IL-4Ralpha and estrogen receptor (ER) alpha compared with macrophages f

123 ted of altering estrogenic signaling through estrogen receptor (ER) alpha or beta (mERbeta1 in mice).

124 ine epithelial proliferation through nuclear estrogen receptor (ER) alpha, but failed to elicit endot

125 18)F-16alpha-17beta-fluoroestradiol (FES) in estrogen receptor (ER) alpha-positive breast cancer cell

126 in the OV/MEPO and ARH were seen to express estrogen receptor (ER) alpha.

127 influences hypothalamic programming through estrogen receptor (ER) alpha.

128 program has screened over 1800 chemicals for estrogen receptor (ER) and androgen receptor (AR) pathwa

129 In addition to the well-known estrogen receptor (ER) and human epidermal growth factor

130 particularly in subgroups defined by cancer estrogen receptor (ER) and progesterone receptor (PR) co

131 Fulvestrant is an estrogen receptor (ER) antagonist administered to breast

132 The estrogen receptor (ER) antagonist ICI 182,780 improved s

133 Tamoxifen, an estrogen receptor (ER) antagonist, is the mainstay treat

134 upregulation of NEMO, the gene that harbored estrogen receptor (ER) binding sites within its promoter

135 Studies of the estrogen receptor (ER) coactivator protein Mediator subu

136 The estrogen receptor (ER) drives the growth of most luminal

137 Estrogen receptor (ER) expression in breast cancer is as

138 rous/menstrual cycle, dynamically modulating estrogen receptor (ER) expression, activity, and traffic

139 e receptor (PR) is usually co-localized with estrogen receptor (ER) in normal mammary cells.

140 The estrogen receptor (ER) is a target for endocrine therapy

141 al and human dosimetry results for the novel estrogen receptor (ER) PET radiotracer 4-fluoro-11beta-m

142 ity" of miRNA hsa-miR-500a was implicated in estrogen receptor (ER) positive breast cancer; however i

143 factor receptor 2 (HER2) positive (n = 51), estrogen receptor (ER) positive/HER2 negative (n = 40),

144 tumors and was most strongly associated with estrogen receptor (ER) positivity (GRPR was high in 83.2

145 Estrogen receptor (ER) recruits steroid receptor coactiv

146 o identify chemicals that may interfere with estrogen receptor (ER) signaling, but the results are di

147 nical stage, posttreatment pathologic stage, estrogen receptor (ER) status, and grade.

148 multinomial logistic regression of outcomes, estrogen receptor (ER) status, lymph node involvement, t

149 Teleost fish express at least three estrogen receptor (ER) subtypes.

150 t cancer cells results in recruitment of the estrogen receptor (ER) to common and distinct genomic si

151 e in two opposing subgroups, which relate to estrogen receptor (ER)(+) luminal A or luminal B and ER(

152 of mammary epithelial cells expressing p27, estrogen receptor (ER), and Ki67 in normal breast tissue

153 The estrogen receptor (ER), glucocorticoid receptor (GR), an

154 brary of small interfering RNAs targeting an estrogen receptor (ER)- and aromatase-centered network i

155 During the first 5 years, patients with estrogen receptor (ER)--positive disease had a lower ann

156 Estrogen and estrogen receptor (ER)-alpha suppress visceral fat devel

157 biopsy of the involved lymph node confirmed estrogen receptor (ER)-positive (90%), progesterone rece

158 tabolites were significantly associated with estrogen receptor (ER)-positive (ER(+)) breast cancer (4

159 that MSI2 expression was highly enriched in estrogen receptor (ER)-positive breast cancer and that M

160 e alpha (PI3Kalpha), are frequently found in estrogen receptor (ER)-positive breast cancer.

161 Greater than 50% of estrogen receptor (ER)-positive breast cancers coexpress

162 The OR was higher for estrogen receptor (ER)-positive disease (2.55 [95%CI, 2.

163 er risk and prognosis is well established in estrogen receptor (ER)-positive disease but less clear i

164 association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease.

165 we have sampled TIF from triple negative and estrogen receptor (ER)-positive human breast tumor xenog

166 lence of ESR1 mutations (Y537S and D538G) in estrogen receptor (ER)-positive MBC and determine whethe

167 F2 induction and nuclear accumulation in the estrogen receptor (ER)-positive MCF7 breast cancer cells

168 Cox regression models among 69 patients with estrogen receptor (ER)-positive/HER2-negative cancer, RS

169 s of luminal breast cancer cells through the estrogen receptor (ER).

170 y, particularly against tumors driven by the estrogen receptor (ER).

171 in (but not mRNA) expression correlates with estrogen receptor (ER+) and progesterone receptor (PGR)

172 d after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer.

173 ry breast cancer tissue and resected BrM (10 estrogen receptor [ER]-negative and 10 ER-positive) from

174 T3 correlated with worse clinical outcome in estrogen receptor+ (ER+) breast cancers.

175 After surgery, patients with estrogen receptor (ERalpha)-positive breast cancer are t

176 In this study, we demonstrate that in the estrogen receptor (ERalpha)-positive LBC cells Twist1 si

177 ice variant of the estrogen receptor, namely estrogen receptor (ERalpha-36), associated with a poor p

178 Estrogen receptors (ERs) are targets for endocrine treat

179 was still able to bind and activate soluble estrogen receptors (ERs) in vitro.

180 Isoflavones have an affinity for estrogen receptors (ERs) including beneficial affinity f

181 cancer, especially in the subtype expressing estrogen receptors (ERs), suggest tissue-specific procli

182 ed NFIB and YBX1 as novel interactors of the estrogen receptor (ESR1).

183 sy indicated that the tumor was positive for estrogen receptor expression (50%), negative for progest

184 udies showed that the tumor was positive for estrogen receptor expression (90%) and for progesterone

185 ing an inducible cell line that expresses an estrogen receptor fusion of the macrophage-specific tran

186 steroid hormone receptors G protein-coupled estrogen receptor (GPER), and progestin and adipoQ recep

187 ad of renal cancer via the G protein-coupled estrogen receptor (GPER).

188 are likely mediated via membrane-associated estrogen receptors; however, the localization and distri

189 that hippocampal GPER may not function as an estrogen receptor in the dorsal hippocampus.

190 erived cells and the purported importance of estrogen receptors in BPH development and/or progression

191 e identified GPER/GPR30, a G-protein-coupled estrogen receptor, in goldfish (Carassius auratus) neura

192 quired host-derived (murine) mtDNA promoting estrogen receptor-independent oxidative phosphorylation

193 a variety of aminopyridines, including known estrogen receptor ligands.

194 iratory insufficiency suggests that membrane estrogen receptors may represent novel therapeutic targe

195 There is evidence that, through selective estrogen receptor modulation, isoflavones may exert bene

196 Tamoxifen, a selective estrogen receptor modulator (SERM), represents the stand

197 tor degeneration that tamoxifen, a selective estrogen receptor modulator and a drug previously linked

198 Tamoxifen, a selective estrogen receptor modulator approved for the treatment o

199 Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase i

200 CNS-permeant PKC inhibitor is the selective estrogen receptor modulator tamoxifen.

201 uvant endocrine therapy, including selective estrogen receptor modulators (SERMs) and/or aromatase in

202 eral FDA-approved drugs, including selective estrogen receptor modulators (SERMs), possess selective

203 eate dual aromatase inhibitor (AI)/selective estrogen receptor modulators (SERMs).

204 Tamoxifen and raloxifene are selective estrogen receptor modulators that have been shown to red

205 s may provide means to develop new selective estrogen receptor modulators with improved profiles.

206 naling regulation of a splice variant of the estrogen receptor, namely estrogen receptor (ERalpha-36)

207 GnRH neurons do not express the estrogen receptor needed for feedback (estrogen receptor

208 o are disproportionately affected by T2D and estrogen receptor negative (ER-) breast cancer.

209 with metastatic dissemination to the bone in estrogen receptor negative breast cancer and is essentia

210 1 is frequent in basal (triple-negative) and estrogen receptor negative tumors.

211 In estrogen receptor-negative (ER(-)) and triple-negative b

212 both estrogen receptor-positive (ER(+)) and estrogen receptor-negative (ER(-)) breast carcinomas.

213 oversampling of premenopausal (n = 582) and estrogen receptor-negative (ER-) cases (n = 462).

214 and receptor status (lower in patients with estrogen receptor-negative and progesterone receptor-pos

215 e-free and overall survival in patients with estrogen receptor-negative breast cancer undergoing chem

216 itive breast cancers (PAR% = 39.7%) than for estrogen receptor-negative breast cancers (PAR% = 27.9%)

217 ical-pathologic scoring system incorporating estrogen receptor-negative disease and nuclear grade 3 t

218 6 to 1.79; P for heterogeneity = .10) versus estrogen receptor-negative disease.

219 an women because of the higher prevalence of estrogen receptor-negative disease.

220 difference, 0.24; P = 2.3 x 10-5), while the estrogen receptor-negative polygenic risk score was much

221 sterone receptor-positive cancer and 63% for estrogen receptor-negative progesterone- receptor-negati

222 We tested the overall effects of estrogen receptors on the immune response by immunizatio

223 In knockout mouse models for estrogen receptor or aromatase, we observed that perturb

224 Rs across breast carcinomas defined by their estrogen receptor or invasive or in situ status.

225 We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERalpha wo

226 ganisations, cell proliferation, cell death, estrogen receptor pathways and phagocytic immune respons

227 Notably, oxytocin and estrogen receptor polymorphisms temper accelerated cellu

228 Early stage estrogen receptor positive (ER+) breast cancer (BCa) tre

229 ifen) at 10 years in the population that was estrogen receptor positive or had unknown estrogen recep

230 In the population that was estrogen receptor positive or had unknown estrogen recep

231 en associated with the differential risks of estrogen receptor positive or negative breast cancers, b

232 er tumors as compared to the less aggressive estrogen receptor positive tumors.

233 Of these, 73 (87%) were estrogen receptor positive, 67 (80%) were progesterone r

234 ctrometry of the EZH2-protein interactome in estrogen receptor positive, breast cancer-derived MCF7 c

235 ive ductal carcinoma, grade 2 of 3, that was estrogen receptor positive, progesterone receptor positi

236 with or without significant expansion, were estrogen receptor positive, which is consistent with bot

237 rent among women whose primary and CBCs were estrogen receptor positive.

238 s, we documented EVI1 overexpression in both estrogen receptor-positive (ER(+)) and estrogen receptor

239 f full-term pregnancy in early adulthood for estrogen receptor-positive (ER(+)) breast cancer later i

240 crine treatment of choice for postmenopausal estrogen receptor-positive (ER(+)) breast cancer patient

241 otein panel for individual CTCs derived from estrogen receptor-positive (ER+) breast cancer patients.

242 Importance: Estrogen receptor-positive (ER+) tumors of the breast ar

243 For estrogen receptor-positive (ER+) tumors, no statisticall

244 elopment of the current standard therapy for estrogen receptor-positive advanced breast cancer.

245 this approach for clinical use, we examined estrogen receptor-positive and progesterone receptor-pos

246 itated by IL4 secreted by adipose tissue and estrogen receptor-positive and triple-negative breast ca

247 that have been shown to reduce the risk for estrogen receptor-positive breast cancer and are approve

248 a support a key role for the PI3K pathway in estrogen receptor-positive breast cancer and suggest tha

249 n mammary gland epithelial cells (HMECs) and estrogen receptor-positive breast cancer cell lines.

250 Tamoxifen therapy for estrogen receptor-positive breast cancer reduces the ris

251 east cancer recurrence risk in patients with estrogen receptor-positive breast cancer who underwent t

252 on recovery (OFR) in women age 40 to 49 with estrogen receptor-positive breast cancer who were premen

253 pproved for tamoxifen-resistant or relapsing estrogen receptor-positive breast cancer, these findings

254 approved (palbociclib) for treating advanced estrogen receptor-positive breast cancer, two major clin

255 ome with an increased risk of postmenopausal estrogen receptor-positive breast cancer.

256 e PAR% for modifiable factors was higher for estrogen receptor-positive breast cancers (PAR% = 39.7%)

257 Half of estrogen receptor-positive breast cancers contain a subp

258 th aromatase inhibitors for the treatment of estrogen receptor-positive breast cancers.

259 CI, 1.14 to 1.66; mC, 0.55), but mainly for estrogen receptor-positive disease (IQ-OR, 1.44; 95% CI,

260 nt 3 CBCs per 100 women by 10 years after an estrogen receptor-positive first breast cancer, an absol

261 a key modifier of ribociclib sensitivity in estrogen receptor-positive MCF-7 breast cancer cells.

262 Eligibility included endocrine-refractory, estrogen receptor-positive metastatic breast cancer.

263 One patient-derived xenograft, the estrogen receptor-positive model T126, was chosen to gen

264 Analyses focus on patients with estrogen receptor-positive or unknown tumors (n = 4,599)

265 The estrogen receptor-positive polygenic risk score built fr

266 vival benefit in premenopausal patients with estrogen receptor-positive primary breast cancer.

267 in of no ink on tumor to avoid reexcision in estrogen receptor-positive progesterone receptor-positiv

268 reast cancer recurrence rates, especially in estrogen receptor-positive subtypes, and overexpression

269 s in the surgical cohort more frequently had estrogen receptor-positive tumors and received adjuvant

270 with systemic therapy alone, particularly in estrogen receptor-positive tumors or when newer agents w

271 ary because the majority of the patients had estrogen receptor-positive tumors that may recur later i

272 se recurrence and benefit of chemotherapy in estrogen receptor-positive, lymph node-negative early-st

273 SNP rs10941679, was associated with risk of estrogen-receptor-positive (ER(+)) breast cancer (per-g

274 gher proportions of positive family history, estrogen receptor+, progesterone receptor+, and/or human

275 ence of breast cancers that are negative for estrogen receptor, progesterone receptor, and ERBB2 (tri

276 No biomarker except for estrogen receptor, progesterone receptor, and human epid

277 No differences were detected in estrogen receptor, progesterone receptor, beta-catenin,

278 d locally performed histopathologic markers (estrogen receptor, progesterone receptor, Ki-67, human e

279 %) had ALND; ALND did not vary based on age, estrogen receptor, progesterone receptor, or HER2 status

280 the Ki-67 protein encoded by the MKI67 gene, estrogen receptor, progesterone receptor, tumor size, an

281 ype is associated with higher percentages of estrogen receptor-, progesterone receptor-, or ki67-posi

282 KC than tamoxifen but lacks affinity for the estrogen receptor, reduces AMPH-stimulated increases in

283 gramming in osteoclasts and that MYC induces estrogen receptor-related receptor alpha (ERRalpha) to r

284 C action in the transcriptional induction of estrogen receptor-related receptor alpha (ERRalpha), a n

285 or-1beta) and the nuclear receptor ERRalpha (estrogen receptor-related receptor alpha), and that SIRT

286 ranscription may be regulated by estrogen or estrogen receptor-related receptors.

287 red in transfected H2.35 cells expressing an estrogen receptor reporter gene, estrogen receptor 1, an

288 those observed in patients and also identify estrogen receptor signaling as critical for protection i

289 ortality, indicating a protective effect for estrogen receptor signaling in mice infected with SARS-C

290 pecific factor(s) such as a reduced estrogen-estrogen receptor signaling in the pathogenesis of AD.

291 cal stage (CS), final pathologic stage (PS), estrogen receptor status (E), and nuclear grade (G) (CPS

292 ears: OR, 0.76; 95% CI, 0.64-0.91), negative estrogen receptor status (positive vs negative: OR, 0.39

293 as estrogen receptor positive or had unknown estrogen receptor status was 2.1% (95% CI, -0.5% to 4.6%

294 as estrogen receptor positive or had unknown estrogen receptor status, 1,111 BCFS events were observe

295 with respect to age, Bloom-Richardson score, Estrogen Receptor status, adjuvant systemic therapy, his

296 Patients with positive margins, unknown estrogen receptor status, and comedo necrosis were more

297 ittle evidence of differential risk by tumor estrogen receptor status.

298 The hormone estrogen (E2) binds the estrogen receptor to promote transcription of E2-respons

299 trogen-agonist or antagonist activity in the estrogen receptor-transactivation assay.

300 m, h-Efp pathway and CARM1 and Regulation of Estrogen Receptor, which can be related to the metastasi